Publication | Closed Access

A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia

Hematological MalignancyOncologyMedicineMixed-phenotype Acute LeukemiaHematologyPharmacotherapyAnti-cancer AgentPharmacologyJapanese PatientsMyeloid Neoplasia